Darin  Lippoldt net worth and biography

Darin Lippoldt Biography and Net Worth

Darin M. Lippoldt J.D. serves as Chief Legal Officer and Corporate Secretary of the Company. He was appointed Chief Legal Officer and Corporate Secretary in October 2014 and has oversight of all corporate legal matters, intellectual property, and corporate compliance. Prior to joining Neurocrine Biosciences, Mr. Lippoldt served as Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary of Volcano Corporation, a company he joined in 2010. Prior to Volcano, Mr. Lippoldt served as Associate General Counsel at Amylin Pharmaceuticals, Inc. since 2003. He previously practiced corporate and securities law with the law firms of Fulbright & Jaworski LLP and Matthews and Branscomb, P.C. Mr. Lippoldt received a B.B.A. in Finance, an M.A. in International Relations and a J.D. from St. Mary’s University.

What is Darin Lippoldt's net worth?

The estimated net worth of Darin Lippoldt is at least $4.95 million as of January 22nd, 2024. Mr. Lippoldt owns 35,882 shares of Neurocrine Biosciences stock worth more than $4,948,845 as of March 29th. This net worth approximation does not reflect any other assets that Mr. Lippoldt may own. Additionally, Mr. Lippoldt receives an annual salary of $921,010.00 as Insider at Neurocrine Biosciences. Learn More about Darin Lippoldt's net worth.

How old is Darin Lippoldt?

Mr. Lippoldt is currently 58 years old. There are 7 older executives and no younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who is 66 years old. Learn More on Darin Lippoldt's age.

What is Darin Lippoldt's salary?

As the Insider of Neurocrine Biosciences, Inc., Mr. Lippoldt earns $921,010.00 per year. There are 4 executives that earn more than Mr. Lippoldt. The highest earning executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who commands a salary of $1,900,000.00 per year. Learn More on Darin Lippoldt's salary.

How do I contact Darin Lippoldt?

The corporate mailing address for Mr. Lippoldt and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected]. Learn More on Darin Lippoldt's contact information.

Has Darin Lippoldt been buying or selling shares of Neurocrine Biosciences?

In the last ninety days, Darin Lippoldt has sold $1,398,600.00 of Neurocrine Biosciences stock. Most recently, Darin Lippoldt sold 10,000 shares of the business's stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $139.86, for a transaction totalling $1,398,600.00. Following the completion of the sale, the insider now directly owns 35,882 shares of the company's stock, valued at $5,018,456.52. Learn More on Darin Lippoldt's trading history.

Who are Neurocrine Biosciences' active insiders?

Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.

Are insiders buying or selling shares of Neurocrine Biosciences?

During the last year, insiders at the sold shares 47 times. They sold a total of 500,477 shares worth more than $64,680,554.88. The most recent insider tranaction occured on March, 21st when insider Ingrid Delaet sold 5,000 shares worth more than $725,300.00. Insiders at Neurocrine Biosciences own 4.4% of the company. Learn More about insider trades at Neurocrine Biosciences.

Information on this page was last updated on 3/21/2024.

Darin Lippoldt Insider Trading History at Neurocrine Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/22/2024Sell10,000$139.86$1,398,600.0035,882View SEC Filing Icon  
12/6/2023Sell20,830$119.86$2,496,683.8035,882View SEC Filing Icon  
11/27/2023Sell10,919$112.27$1,225,876.1335,882View SEC Filing Icon  
11/3/2022Sell4,518$125.02$564,840.3629,234View SEC Filing Icon  
11/1/2022Sell10,000$120.09$1,200,900.0029,234View SEC Filing Icon  
10/27/2022Sell4,923$115.04$566,341.9229,234View SEC Filing Icon  
3/22/2022Sell8,455$95.05$803,647.75View SEC Filing Icon  
3/18/2022Sell300$95.00$28,500.00View SEC Filing Icon  
7/9/2020Sell1,657$136.02$225,385.1427,678View SEC Filing Icon  
5/18/2020Sell5,000$120.00$600,000.0031,021View SEC Filing Icon  
11/8/2019Sell10,000$110.01$1,100,100.0026,728View SEC Filing Icon  
9/3/2019Sell6,736$100.00$673,600.00View SEC Filing Icon  
8/27/2019Sell3,264$100.05$326,563.2021,625View SEC Filing Icon  
8/23/2019Sell1,664$100.09$166,549.7621,625View SEC Filing Icon  
7/30/2019Sell15,831$92.13$1,458,510.03160,732View SEC Filing Icon  
1/3/2018Sell1,979$79.36$157,053.44View SEC Filing Icon  
12/28/2017Sell15,237$75.00$1,142,775.00View SEC Filing Icon  
12/28/2017Sell15,237$75.00$1,142,775.0028,394View SEC Filing Icon  
12/8/2017Sell2,955$75.00$221,625.0016,112View SEC Filing Icon  
12/4/2017Sell6,279$75.04$471,176.1619,436View SEC Filing Icon  
11/15/2017Sell9,900$73.05$723,195.00View SEC Filing Icon  
11/9/2015Sell23,761$52.92$1,257,432.12View SEC Filing Icon  
See Full Table

Darin Lippoldt Buying and Selling Activity at Neurocrine Biosciences

This chart shows Darin Lippoldt's buying and selling at Neurocrine Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Neurocrine Biosciences Company Overview

Neurocrine Biosciences logo
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $137.92
Low: $135.97
High: $138.72

50 Day Range

MA: $137.27
Low: $130.40
High: $143.74

2 Week Range

Now: $137.92
Low: $89.04
High: $148.37

Volume

1,245,663 shs

Average Volume

1,018,999 shs

Market Capitalization

$13.72 billion

P/E Ratio

56.99

Dividend Yield

N/A

Beta

0.25